Skip to main content
Premium Trial:

Request an Annual Quote

Philip Vorwald, Jay LeCoque, Sir Walter Bodmer

Premium
Celsis International this week announced the appointment of Philip Vorwald as vice president and general manager of its Celsis In Vitro Technologies division.
 
Vorwald will be responsible for setting and overseeing the long-term growth strategy of Celsis IVT's ADME-Tox products. Vorwald will report directly to Celsis' CEO, Jay LeCoque.
 
Prior to joining Celsis, Vorwald served as the senior vice president of commercial operations for Cytonome. Prior to joining Cytonome, Vorwald held numerous domestic and overseas management positions with Becton Dickinson's biosciences division. He also worked for Guava Technologies and Delphi in new and emerging business development capacities.
 

 
Oxford Genome Sciences (OGeS) announced this week that it has appointed to its scientific advisory board Sir Walter Bodmer, currently head of the cancer and immunogenetics laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford.
 
Bodmer is researching the fundamental genetic and biological changes that lead to the development of colorectal cancer. OGeS and Bodmer's team will collaborate on the evaluation of OGeS cancer drug candidates in the area of colorectal cancer.
 
Prior to the Weatherall Institute, Bodmer was the director general of the Imperial Cancer Research Fund. Before joining the Imperial Cancer Research Fund, he was a professor of genetics at the University of Oxford. Bodmer moved to Oxford from Stanford University where he was also a professor of genetics.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.